John Foglesong is the CEO and co-founder of Grannus. He brings over 20 years of broad-based experience across the biotech and pharmaceutical industry, having held leadership roles in both large global organizations and emerging biotech companies. His multidisciplinary background spans manufacturing, portfolio and strategic planning, commercial operations, sales and marketing, and new product planning. Most recently, Mr. Foglesong led the commercialization and scale-up of an allogeneic T-cell therapy matching platform at Atara Biotherapeutics. Prior to that, he spent nearly a decade at Genentech, where he held key roles in strategic planning, portfolio management, commercial operations, and marketing—contributing to multiple product launches and lifecycle strategies across oncology, neurosciences, and endocrinology. Earlier in his career, he served as a management consultant in the life sciences practice at Oliver Wyman and held technical and quality roles in fill/finish manufacturing at Eli Lilly. Mr. Foglesong earned his MBA from the Tuck School of Business at Dartmouth and holds a B.S. in Mechanical Engineering from Northwestern University.